These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27643871)

  • 61. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia.
    King A; Shenoy S
    Blood; 2014 May; 123(20):3089-94; quiz 3210. PubMed ID: 24511087
    [No Abstract]   [Full Text] [Related]  

  • 62. Reply to S. Fuji et al.
    Hamadani M; Vos JA; Craig MD
    J Clin Oncol; 2014 Jun; 32(17):1860-1. PubMed ID: 24799471
    [No Abstract]   [Full Text] [Related]  

  • 63. The need to promote all pediatric stem cell donors' understanding and interests.
    Ross LF; Antommaria AH
    Pediatrics; 2014 May; 133(5):e1356-7. PubMed ID: 24777208
    [No Abstract]   [Full Text] [Related]  

  • 64. Alternative donors: a match for matched sibling donors?
    Inamoto Y
    Lancet Haematol; 2019 Nov; 6(11):e545-e546. PubMed ID: 31477551
    [No Abstract]   [Full Text] [Related]  

  • 65. Quality-of-life monitoring during hematopoietic stem cell transplantation: observations and a suggestion from the rome transplant network quality of life working party.
    Tendas A; Pignatelli AC; Sollazzo F; Veggia B; Conte E; D'Apolito A; Di Veroli A; Molinari V; Mauroni M; Annibali O; Pilozzi V; Cacciaraichi S; Viggiani C; Niscola P; de Fabritiis P; Arcese W;
    J Pain Symptom Manage; 2013 Apr; 45(4):e2-3. PubMed ID: 23499456
    [No Abstract]   [Full Text] [Related]  

  • 66. "Risk adapted" assessments of health related quality of life in HSCT recipients.
    Kline RM
    Pediatr Blood Cancer; 2011 Dec; 57(7):1095-6. PubMed ID: 21681932
    [No Abstract]   [Full Text] [Related]  

  • 67. Does rehabilitation have a place in oncology management?
    Cole RP; Scialla SJ
    Ann Oncol; 2002 Feb; 13(2):185-6. PubMed ID: 11885992
    [No Abstract]   [Full Text] [Related]  

  • 68. Authors' reply to Tendas et al.
    Cohen MZ; Rozmus CL; Mendoza TR; Padhye NS; Neumann J; Gning I; Aleman A; Giralt S; Cleeland CS
    J Pain Symptom Manage; 2013 Apr; 45(4):e3-4. PubMed ID: 23544910
    [No Abstract]   [Full Text] [Related]  

  • 69. Speaker's corner. Living with thalassemia.
    Compagno LM
    West J Med; 2000 Feb; 172(2):138-9. PubMed ID: 10693380
    [No Abstract]   [Full Text] [Related]  

  • 70. Family reflections: thalassemia and Ammar.
    Oonwala A
    Pediatr Res; 2022 Jun; 91(7):1913-1914. PubMed ID: 34983938
    [No Abstract]   [Full Text] [Related]  

  • 71. Systematic Review and Meta-Analysis of Health-Related Quality of Life in Patients with β-Thalassemia that Underwent Hematopoietic Stem Cell Transplantation.
    Mulas O; Pili I; Sanna M; La Nasa G
    Clin Pract Epidemiol Ment Health; 2023; 19(Suppl-1):e174501792301031. PubMed ID: 38659631
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term health-related quality of life in patients with β-thalassemia after unrelated hematopoietic stem cell transplantation.
    Mulas O; Caocci G; Efficace F; Piras E; Targhetta C; Frau V; Barella S; Piroddi A; Orofino MG; Vacca A; La Nasa G
    Bone Marrow Transplant; 2022 Dec; 57(12):1833-1836. PubMed ID: 36114248
    [No Abstract]   [Full Text] [Related]  

  • 73. The Future of Gene Therapy for Transfusion-Dependent Beta-Thalassemia: The Power of the Lentiviral Vector for Genetically Modified Hematopoietic Stem Cells.
    Rattananon P; Anurathapan U; Bhukhai K; Hongeng S
    Front Pharmacol; 2021; 12():730873. PubMed ID: 34658870
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hematopoietic stem cell transplantation for thalassemia major using HLA fully-matched and mismatched donor grafts.
    Huang C; Qu Y; Liu S; Nie S; Jiang H
    Transl Pediatr; 2021 Jun; 10(6):1552-1565. PubMed ID: 34295770
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.
    Kansal AR; Reifsnider OS; Brand SB; Hawkins N; Coughlan A; Li S; Cragin L; Paramore C; Dietz AC; Caro JJ
    J Mark Access Health Policy; 2021 Jun; 9(1):1922028. PubMed ID: 34178295
    [No Abstract]   [Full Text] [Related]  

  • 76. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy.
    Badawy SM; Beg U; Liem RI; Chaudhury S; Thompson AA
    Blood Adv; 2021 Jan; 5(2):570-583. PubMed ID: 33496753
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Health-related quality of life (HRQoL) in beta-thalassemia major (β-TM) patients assessed by 36-item short form health survey (SF-36): a meta-analysis.
    Arian M; Mirmohammadkhani M; Ghorbani R; Soleimani M
    Qual Life Res; 2019 Feb; 28(2):321-334. PubMed ID: 30194626
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Return to normal life after hematopoietic stem cell transplantation for thalassemia: a study of patients transplanted from matched sibling donors.
    Caocci G; Vacca A; Piras E; Serreli V; Dessi C; Marcias M; Risso P; La Nasa G
    Bone Marrow Transplant; 2016 Dec; 51(12):1640-1641. PubMed ID: 27643871
    [No Abstract]   [Full Text] [Related]  

  • 79. Innovative approaches to hematopoietic stem cell transplantation for patients with thalassemia.
    Locatelli F; De Stefano P
    Haematologica; 2005 Dec; 90(12):1592-4. PubMed ID: 16330431
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.